What to watch with CYP1A2 and menopause?

CYP1A2 is a key enzyme for metabolizing caffeine and estrogens. During menopause, estrogen production declines, which may indirectly reduce CYP1A2 activity because estrogen induces this enzyme. This means postmenopausal women might clear caffeine more slowly and become more sensitive to its effects. Additionally, certain CYP1A2 variants (e.g., rs762551) have been linked to breast cancer risk depending on hormone exposure, but these findings come mainly from mechanistic and epidemiological studies, not from randomized trials. Therefore, a direct genetic test for CYP1A2 in the context of menopause has limited clinical utility. Practical advice includes moderating caffeine intake, monitoring sleep quality, and consulting a doctor for symptoms like hot flashes or palpitations. The evidence is rated as 'mechanistic/mixed' – no strong clinical guidelines currently recommend specific CYP1A2-based actions during menopause.